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ABSTRACT
Background: The liver is a common metastatic site for a large variety of primary 
tumors. For both patients with known and unknown primary tumors it is important 
to understand metastatic patterns to provide tailored therapies.
Objective: To perform a nationwide exploration of the origins of histological 
confirmed liver metastases.
Results: A total of 23,154 patients were identified. The majority of liver 
metastases were carcinomas (n=21,400; 92%) of which adenocarcinoma was the 
most frequent subtype (n=17,349; 75%). Most common primary tumors in patients 
with adenocarcinoma were from colorectal (n=8,004), pancreatic (n=1,755) or breast 
origin (n=1,415). In women of 50 years and younger, metastatic adenocarcinoma 
originated more frequently from breast cancer, while in women older than 70 years 
liver metastases originated more frequently from gastrointestinal tumors. Liver 
metastases in men older than 70 years originated often from squamous cell lung 
carcinoma. An unknown primary tumor was detected in 4,209 (18%) patients, 
although tumor type could be determined in 3,855 (92%) of them.
Methods: Data were collected using the nationwide network and registry of 
histo- and cytopathology in the Netherlands (PALGA). All histological confirmed liver 
metastases between January 2001 and December 2010 were evaluated for tumor 
type, origin of the primary tumor and were correlated with patient characteristics 
(age, gender).
Conclusion: The current study provides an overview of the origins of liver 
metastases in a series of 23,154 patients.
INTRODUCTION
The liver is a common site for metastatic 
disease, however, little is known about the frequency 
in which various tumors present with liver metastases. 
Understanding these metastatic patterns is important 
for patients with a known primary tumor, as well as for 
patients with an unknown primary tumor. Knowledge of 
preferred metastatic sites in the first group of patients may 
direct staging and surveillance schemes, while in the group 
of patients with an unknown primary tumor the patterns 
can be used to predict the primary tumor site, which is 
important for treatment.
The high frequency of liver involvement in 
metastatic disease can be explained by the different 
hypotheses of metastatic spread. The double blood supply 
of the liver by the portal vein and the hepatic artery 
facilitates entrapment of circulating cancer cells, according 
to the “mechanical or hemodynamic hypothesis” [1], 
which explains the high incidence of liver metastases in 
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patients with gastrointestinal carcinomas. However, some 
primary tumors selectively target the liver as a metastatic 
location, according to the “seed-and-soil” hypothesis [2]; 
examples are patients with uveal melanoma with a loss of 
chromosome 3 [3] , and patients with breast cancer with 
the human growth factor receptor 2 (HER-2) positivity in 
combination with estrogen (ER) and progesterone receptor 
(PR) positivity [4].
Metastatic patterns in colorectal cancer have 
recently been evaluated in a large nationwide autopsy 
study, describing all autopsies between 1991-2010 [5]. 
Hugen et al. demonstrated development of liver metastases 
in 32%-73% of the colorectal cancer patients, with 
significant differences between various histological 
subtypes [5]. While it is known that the majority of the 
liver metastases are of colorectal origin, exact data about 
incidences of non-colorectal liver metastases are scarce.
Large scale autopsy studies could potentially provide 
information, but these studies are rare, and often based 
on much older cohorts [6, 7]. An example is the study 
of DiSibio et al. which describes a cohort of autopsies 
between 1914 and 1943 [6]. Since 1943 changes in both 
surgical treatment and adjuvant therapy are profound and 
likely to have influenced detection and development of 
liver metastases. To date, it remains unclear which primary 
tumors, other than colorectal cancer, metastasize to the 
liver and in which frequency they do so.
By analyzing all liver biopsies in an era of 
modern diagnostics and treatments, the incidences of 
liver metastases can be estimated for different primary 
tumors. This large scale, systematic, nationwide analysis 
of pathology reports generated between 2001 and 2010 
showed new insights into the origins of liver metastases.
RESULTS
General patient characteristics
During the study period, 24,136 pathology reports 
(20,098 liver biopsies and 4,038 liver resections) were 
retrieved. Double counts were excluded for 982 patients 
who underwent both a liver biopsy and liver surgery 
(n=390), patients who underwent multiple liver resections 
(n=342) or patients who underwent more than one liver 
biopsy (n=250). A total of 23,154 patients were included 
in the study (47% female). Median age at the time of 
liver biopsy was 67 years (range 0-97 years), and 63 
years (range 1-91years) at the time of liver resection. 
The patients who underwent a liver biopsy at the age of 0 
(n=3), were diagnosed with neuroblastoma, while the one-
year old patient underwent a liver resection for metastatic 
Wilms tumor.
The amount of liver biopsies did not significantly 
increase over time. In 2001, 1,934 biopsies were 
performed, compared to 2,232 in 2010. In contrast, there 
was a significant decrease in pre-operative biopsies, from 
10.8% in 2001 to 8.8% in 2010 (p<0.001). An increase of 
liver resections was observed; from 224 in 2001 to 596 in 
2010 (p<0.0001).
Tumor types and organs of origin
Carcinoma was the most frequent tumor type, 
diagnosed in 21,400 patients (92.4%), followed by 
melanoma in 547 patients (2.4%), and sarcoma in 235 
patients (1.0%). In 33 patients (0.1%) the tumor type was 
classified as ‘other’. The pathologist was unable to define 
the tumor type of the liver metastases in 938 patients (4.1%). 
(For detailed information see Supplementary Table S1)
Carcinoma
Adenocarcinoma not otherwise specified (N.O.S.) 
was the most frequent subtype of carcinoma (n=17,349; 
74.9%), followed by small cell carcinoma (n=1357, 5.9%), 
neuroendocrine carcinoma (n=1072; 4.6%), large cell 
carcinoma (n=877; 3.7%), and squamous cell carcinoma 
(n=335; 1.4%). (See Supplementary Table S1).
The majority of adenocarcinoma N.O.S. originated 
from the digestive tract (n=11,829; 68.2%), especially from 
colorectal origin (n=8,004; 46.1%). In 2,709 patients (15.6%), 
the primary tumor location was not specified (Figure 1). For 
detailed information see Supplementary Table S2.
Liver metastases of the small cell subtype were 
most often of pulmonary origin (n=1043; 76.9%). Primary 
tumor location was not specified in 268 patients (19.7%). 
(Supplementary Table S2).
Neuroendocrine liver metastases originated most 
frequently from the digestive tract (n=389; 36.3%), 
especially from the pancreas (n=137; 12.8%) and 
duodenum (n=110; 10.3%). Pulmonary origin was 
observed in 238 patients (22.2%), and in 416 patients 
(38.8%) the primary tumor location was not specified 
(Supplementary Table S2, Figure S1).
The primary tumor in large cell carcinoma liver 
metastases was most frequently located in the lung 
(n=305; 34.8%), followed by digestive tract (n=97; 11.1%) 
and urological tract (n=41; 4.7%). Primary tumor location 
was not specified in 376 patients (42.9%) (Figure 1) 
(Supplementary Table S2).
Squamous cell carcinoma liver metastases 
originated most often from the lung (n=118; 35.2%) or 
the digestive tract (n=66; 18.6%), more specifically from 
the esophagus (n=39; 11.6%). In 44 patients (12.4%) the 
primary tumor was located in the oropharynx. Primary 
tumor location was not specified in 72 patients (21.5%) 
(Figure 1) (Supplementary Table S2).
Melanoma
Metastatic melanoma was observed in 547 patients 
(2.4%) with liver metastases. Uveal melanoma was the 
primary tumor in 213 patients (38.9%), and primary 
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cutaneous melanoma was the origin of liver metastases 
in 251 patients (45.8%). Liver metastases from mucosal 
melanoma were rare, with primary locations in the colon 
(n=3), small bowel (n=1), and urinary bladder (n=1). In 
78 patients, the primary melanoma location was unknown 
(Supplementary Table S1).
Sarcoma
Metastatic sarcoma was observed in 235 patients 
(1.0%) with liver metastases. The most prevalent subtype 
of metastatic sarcoma was gastrointestinal stromal tumor 
(GIST) (n=107; 45.5%), followed by leiomyosarcoma 
(n=64; 27.2%), and sarcoma N.O.S. (n=47; 20.0%) 
(Supplementary Table S1).
For GIST metastases, the following primary 
locations were described; colon or rectum (n=8), stomach 
(n=48), small bowel (n=22), and digestive tract N.O.S. 
(n=10). In 18 reports the primary GIST location was not 
specified.
Primary tumor locations in patients with metastatic 
leiomyosarcoma were: colon (n=1), stomach (n=4), small 
bowel (n=6), uterus (n=14), ovary (n=1), kidney (n=2), 
bone/soft tissue (n=33), or digestive tract (n=1). In 2 reports 
the location of the primary tumor location was not specified.
Primary tumor locations in patients with metastatic 
sarcoma N.O.S. were: bone/soft tissue (n=16); brain/
meningeal (n=4); skin (n=2); rectum (n=1); oropharynx/
nasopharynx (n=1) and small intestine (n=1). There was 
an unknown primary tumor location in 19 patients.
Gender differences in primary tumor locations
Histological confirmed liver metastases were more 
often observed in men than in women (n=12,280; 53.0% 
versus n=10,874; 47.0%; p<0.0001). Liver metastases 
from carcinoma (n=11,397; 53.3%; p=0.017), and 
melanoma (n=322; 58.9%; p=0.006) were more frequently 
diagnosed in men, whereas more women were diagnosed 
with liver metastases from an unknown tumor type (n=514; 
54.8%; p<0.0001). In patients with liver metastases from 
carcinoma subtypes, male predominance was particularly 
observed in liver metastases with the subtypes: large cell 
carcinoma, small cell carcinoma, transitional carcinoma, 
and squamous cell carcinoma (Figure 2) (Supplementary 
Table S1).
Men presented relatively more often with liver 
metastases from colorectal adenocarcinoma compared to 
women [40.7% (n=4,625) versus 31.6% (n=3,379) (OR 
1.63; 95%CI: 1.53-7.73; p<0.0001)].
Figure 1: Origins of liver metastases of the carcinoma type. Each clock plot shows the origins of liver metastases per carcinoma 
subtype (adenocarcinoma, small cell carcinoma, neuroendocrine carcinoma, large cell carcinoma, squamous cell carcinoma). Outer circles 
represent the location of the primary tumor. Circle size is proportional to the number of metastases.
Oncotarget55371www.impactjournals.com/oncotarget
Liver metastases from squamous cell lung 
carcinoma was more frequently observed in men than 
in women [45.7% (n=91) versus 19.9% (n=27) (95%CI: 
2.052-5.638; p<0.0001)].
Age differences
The majority of patients with liver metastases was 
older than 50 years (90.2%; n=20,892).
Metastatic adenocarcinoma from the digestive 
tract (including colorectal carcinoma liver metastases) 
were more common in older women (>70 years) than in 
younger women (≤50 [62.6% (n=1,823), versus 45.5% 
(n=540) (OR: 2.00; 95%CI: 1.75-2.30; p<0.0001)].
In contrast, a relative increased frequency of breast 
adenocarcinoma liver metastases was observed in younger 
women (≤50 years), compared to older women (>70 years) 
[34.2% (n=406) versus 8.9% (n=251) (OR 5.35; 95%CI 
4.49-6.38; p<0.0001)]. There was no difference between 
young and older women in metastatic gynecological 
adenocarcinomas; 3.3% (age <50 years) versus 4.2% (age 
51-70) versus 3.2% (age >70) (Figure 3A).
However, metastatic squamous cell carcinomas 
and metastatic neuroendocrine carcinomas from the 
gynecologic tract were more frequently observed in 
young women (≤50 years, compared to women older 
than 50 years [38.9% (n=7) versus 16.1% (n=19) (OR: 
4.13; 95%CI: 1.47-11.57; p=0.007) respectively, 4.8% 
(n=3) versus 1.0% (n=4) (OR: 5.19; 95%CI: 1.13-23.75; 
p=0.034)] (Figure 3B and 3C).
Metastatic adenocarcinoma originated relatively 
more frequent from urological tumors in men, and 
especially in men older than 50 years [3.1% (n=249) 
versus 0.9% in younger men (≤50 years) (n=6) (OR: 3.7; 
95%CI: 1.51-8.94; p=0.04)] (Figure 3A).
In older men (>70 years), liver metastases from 
squamous cell lung carcinoma were more frequent than 
in younger men (≤50 years) [46.4% (n=26) versus 18.1% 
(n=4) (OR: 3.90; 95%CI: 1.17-13.00; p=0.027)]; liver 
metastases from squamous cell lung carcinoma were 
most common in middle aged male patients (51-70 years) 
(n=61; 50.4%) (Figure 3C).
Unknown primary tumors
After reviewing all pathology history and follow 
up, there were 4,317 patients (18.6%) without a primary 
tumor location. In most of these unsolved cases, tumor 
type was reported (n=3,963; 91.8%). Carcinoma was the 
most common tumor type (n=3,847; 89.1%), and the most 
prevalent tumor subtype was adenocarcinoma N.O.S. 
(n=2,709; 62.8%).
There was a small male predominance in patients 
with an unknown primary (n=2,262; 52.4%).
Median age of patients with an unknown primary 
tumor was 68 years (range 0-96 years).
Patients with metastatic adenocarcinoma from an 
unknown primary tumor were significantly older at time 
of diagnosis, compared to patients with adenocarcinoma 
from a known primary tumor location; 68 years (range 25-
96 years) versus 66 years (range 20-97 years) (p<0.0001). 
Median age of patients with an unknown primary from 
other tumor types and subtypes did not significantly differ 
from the age of patients with a known primary tumor.
Figure 2: Differences in gender between tumor types A. and the most important carcinoma subtypes B. #: no significant difference 
between women and men.
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DISCUSSION
To the authors’ knowledge, this is the first population-
based study that describes the origins of histological 
confirmed liver metastases in a systematic way, including 
more than 23,000 patients during a 10-year time frame. 
The current study provides modern data on the origin and 
incidence of histological confirmed liver metastases from 
both biopsies and resection specimens in an era in which 
patients are treated according to modern standards.
Older cohort studies may represent a close 
approximation for the progression of untreated malignancies 
in humans [6], but it is of no doubt that in time metastatic 
patterns of various malignancies have changed. In the 
autopsy study by DiSibio et al. the primary tumors that 
spread most frequently to the liver included testicular cancer 
and breast cancer [6]. In that cohort testicular cancer spread 
to the liver in 75% of the patients, while in the present study 
the amount of liver metastases from testicular cancer was 
almost negligible, partly due to the fact that these tumors 
are currently diagnosed with markers in blood or by 
using imaging techniques [6]. Moreover, with the current 
treatment of resection and systemic therapy, the prognosis 
of testicular cancer improved tremendously and as a result, 
histological confirmed liver metastases are diagnosed less 
frequently nowadays [8, 9].
Reported incidences of breast cancer liver 
metastases also differed between autopsy studies and data 
of the present study [6, 10]. In time, a major improvement 
for breast cancer patients was made by the introduction 
of breast cancer screening programms [11], In addition, 
changes in chemotherapy, post-operative radiotherapy and 
hormonal therapy resulted in improved prognosis and led 
to decreased incidences in breast cancer liver metastases 
[6, 10, 12–14].
As to be expected, carcinoma was by far the 
most common tumor type (92%), more specifically 
adenocarcinoma N.O.S. (75%), found in patients with 
liver metastases. The most common primary tumor was 
colorectal carcinoma (35%). Liver resection was most 
often performed in patients with metastatic colorectal 
cancer, as was recently reported [15].
In general, gender distribution of the primary 
tumors corresponded with gender distribution of the 
liver metastases, although some remarkable differences 
were observed. Liver metastases from thyroid cancer 
were more frequently diagnosed in male patients (51.3%) 
while, according to the Dutch national cancer registry, 
primary thyroid carcinoma is more prevalent in women 
(approximately 73% of all thyroid cancer types). Despite 
the small number of patients with liver metastases from 
thyroid cancer, this might suggest that the behavior of 
Figure 3A: Relative incidences of primary tumor locations in women and men with metastatic adenocarcinoma. In 
young women, metastatic breast cancer was more frequently observed (p<0.0001). Liver metastases from urological tumors were more 
frequently observed in men older than 50 years (p<0.0001). (Continued )
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Figure 3B: Relative incidences of primary tumor locations in women and men with metastatic neuroendocrine tumor. 
In young women (≤50 years), the primary tumor was significantly more often located in the gynecological tract (p=0.034).
Figure 3C: Relative incidences of primary tumor locations in women and men with metastatic squamous cell carcinoma. 
Liver metastases from the gynecological tract were more frequently observed in women ≤ 50 years (p=0.007). Primary tumor location in 
the lung was observed significantly more frequent in men older than 50 years (p=0.41).
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thyroid carcinoma in male patients is more aggressive, 
which is confirmed by a worse prognosis in male patients 
[16]. Similar findings were observed in male patients with 
liver metastases from cutaneous melanoma. Although 
primary cutaneous melanoma is more frequently observed 
in female patients (58.3%, according to the Dutch National 
Cancer Registry), male patients are more frequently 
diagnosed with liver metastases (59%). Again this seems 
to be the result of aggressive tumor behavior in male 
patients [17, 18].
The clinical value of the present data might be 
questioned, but they can be used in the process of clinical 
decision making. In patients with multiple primary tumors 
and liver metastases, an approximation of the relative 
frequency of liver metastases can be derived from the 
current study. This could guide additional diagnostic 
(e.g.biopsy, immohistochemistry) or treatment strategies 
(e.g. surgery, systemic therapy).
The current overview can also be used for clinical 
decision making in patients with cancer of an unknown 
primary tumor (CUP). CUP is defined as a presentation 
of histologically confirmed metastases, where, despite 
a standardized diagnostic approach, no primary tumor 
can be detected [19]. In 24%-50% of the patients with 
CUP liver metastases are found [20–22]. Understanding 
the pathophysiological and molecular biology is needed 
to improve selective treatment strategies, based on the 
primary tumor and in the end to improve survival in 
patients with CUP. The current large dataset might be a 
basis for further research in this group of patients.
Despite the size of this large, nation-wide population 
based study, selection bias should not be underestimated. 
Obviously, not all patients with liver metastases will 
undergo liver biopsy. Especially in case of colorectal 
cancer liver metastases, the start of systemic treatment 
is often based on radiological diagnosis (CT-scan or 
FDG-PET scan) rather than on histological confirmation. 
Furthermore, although the liver is usually an easy access 
for biopsy, it is possible that histological or cytological 
confirmation was obtained from other metastatic sites 
such as: lymph nodes, ascites, pleural fluid, pulmonary 
lesions or any other metastatic location. Since these data 
and treatment, other than surgery, were not available in 
the current study, data on survival were not reported. On 
the other hand, many studies describe excellent results in 
patients diagnosed with liver metastases who underwent 
liver resection. This is not only the case in patients with 
colorectal cancer liver metastases, but improved survival 
has been reported in patients with other primary tumors, 
such as: breast cancer, melanoma, GIST or renal cell 
carcinoma [23–26].
In conclusion, this study provides an overview 
of the origins of liver metastases, with regard to tumor 
type, age and gender, in an era of modern diagnostic and 
treatment modalities. These important data form a basis 
for future research, and can be used for the development 
of diagnostic strategies.
MATERIALS AND METHODS
Patients and data collection
Data were collected using a search question with 
keywords in the PALGA-database; the nation-wide 
network and registry of histo-and cytopathology in 
the Netherlands. This network registers all pathology 
reports since 1971, with a nation-wide coverage since 
1991 [27]. With the key words; “liver metastases”, 
“histology”, and limited to the years “2001-2010”, 
all pathology reports describing liver metastases were 
identified.
Pathology reports were excluded when patients 
underwent a liver resection or liver biopsy for a benign 
liver condition or for a primary malignant liver tumor such 
as hepatocellular carcinoma.
Per patient the following characteristics were 
collected from the pathology report: age and gender, the 
year of first histological diagnosis (in case of multiple 
biopsies, or a biopsy prior to liver resection), tumor type 
and subtype, and the location of the primary tumor.
For age three categories were used: 50 years and 
younger; between 51 and 70 years; and over 71 years. The 
patient’s age at the first time of histological diagnosis was 
used in the analysis.
Tumor type and subtype were defined according to 
the International Classification of Disease (ICD-10). When 
the origin of the primary tumor was not described in the 
conclusion of the pathology report, additional reports of 
that patient were collected and evaluated to identify the 
primary tumor. When, after this assessment, no primary 
tumor could be detected, the primary tumor was classified 
as an “unknown primary”. Anonymous data were used and 
both the privacy committee and scientific committee of 
PALGA approved the study design.
Statistical analysis
The chi-square test was used to compare nominal 
variables and the Mann-Whitney U test was used to 
compare continuous variables. A p-value of less than 0.05 
was considered to be statistically significant. Multivariate 
regression analyses were used to determine differences 
in primary tumor locations between men and women in 
the age categories. All descriptive and statistical analyses 
were performed using statistical package for social 
sciences (SPSS, INC., Chicago, Illinois, USA version 
18.0). Cytoscape version 3.2.1. was used to perform clock 
plots to visualize the origins of liver metastases of the 
carcinoma type. Circle size is the square root of the total 
number of liver metastases.
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